We market medicines that are designed to improve the health and quality of life of patients in the UK

The content on this page is intended for members of the public.

Arimidex® (anastrozole) GB  
Bambec® (bambuterol) GB  
Bevespi® (glycopyrronium / formoterol fumarate dihydrate) GB  
Bricanyl® (terbutaline sulphate) GB  
Brilique® (ticagrelor) GB NI
Bydureon® (exenatide) GB NI
Byetta® (exenatide) GB NI
Calquence® (acalabrutinib) GB NI
Casodex® (bicalutamide) GB  
Crestor® (rosuvastatin) GB  
Daxas® (roflumilast) GB  
Duaklir® Genuair (aclidinium/formoterol) GB  
Eklira® Genuair (aclidinium/bromide) GB  
Fasenra® (benralizumab) GB NI
Faslodex® (fulvestrant) GB NI
Fluenz Tetra® (live attenuated, nasal) GB NI
Forxiga® (dapagliflozin) GB NI
IMFINZI® (durvalumab) GB NI
Iressa® (gefitinib) GB NI
Komboglyze® (saxagliptin/metformin hydrochloride) GB NI
Losec® (omeprazole) GB  
Lokelma® (sodium zirconium cyclosilicate) GB NI
Nexium® (esomeprazole) GB  
Onglyza® (saxagliptin) GB NI
Oxis® Turbohaler (formoterol) GB  
Lynparza® (olaparib) GB NI
Plendil® (felodipine) GB  
Pulmicort® (budesonide) GB  
Qtern® (dapagliflozin/saxagliptin) GB NI
Symbicort® (budesonide/formoterol) GB  
TAGRISSO® (osimertinib) GB NI
Tenormin® (atenolol) GB  
Tenoret 50® (atenolol/chlorthalidone) GB  
Tenoretic® (atenolol/chlorthalidone) GB  
Tenif® (atenolol/nifedipine) GB  
Trixeo® (budesonide, formoterol fumarate dihydrate, glycopyrronium) GB  
Xigduo® (dapagliflozin/metformin) GB NI
Zestoretic® (lisinopril dehydrate/hydrochlorothiazide) GB  
Zestril® (lisinopril) GB  
Zoladex® (goserelin) GB  

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See for how to report side effects.


Other resources

Report an adverse event

All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug's therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable.

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to AstraZeneca on 0800 783 0033 and via

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine.

For medical enquiries about our products (including questions on how to take your medicine, to report a side effect or make a complaint regarding one of our medicines).

Please contact our UK based Medical Information team

Call: 0800 783 0033.

Lines are open from Monday-Friday, 9am - 5pm. Outside these hours and on bank holidays, an out of hours service is available to assist with urgent enquiries.

VVPM ID: GB-28926 Date of Prep: May 2021